Perbedaan Timah Tbk. dan Tempo Scan Pacific Tbk.: Timah Tbk. diperdagangkan di Rp3.740 (kapitalisasi pasar 28,6 T, volume 24 jam 23,73 jt), sedangkan Tempo Scan Pacific Tbk. diperdagangkan di Rp2.780 (kapitalisasi pasar 12,58 T, volume 24 jam 216,9 rb). Perbedaan utamanya: Timah Tbk. jauh lebih besar — sekitar 2,3× kapitalisasi pasar Tempo Scan Pacific Tbk., dan Timah Tbk. lebih aktif diperdagangkan (23,73 jt vs 216,9 rb). Mana yang lebih baik tergantung tujuan investasimu.
| TINS | TSPC | |
|---|---|---|
Kapitalisasi Pasar | 28,6 T | 12,58 T |
Volume | 23,73 jt | 216,9 rb |
Lot | 237,31 rb | 2,17 rb |
Perputaran | 88,99 M | 599 jt |
Harga Rata-rata | 3.749,96 | 2.761,65 |
Nilai Transaksi | 88,99 M | 599 jt |
Harga Ekuilibrium Indikatif | 3.860 | 2.790 |
Volume Ekuilibrium Indikatif | 2,37 rb | 3,9 rb |
Imbal hasil berjalan pada periode standar
Berita terbaru kedua aset
PT Timah Tbk (Company) was officially establish by Imas Fatimah, SH by Notarial Deed No.1 dated 2 August 1976. The Company represents a merger of three Dutch Mining companies with operations in Indonesia. The Company’s registration statement in offer 50.330.000 new B class shares at par value of Rp. 500 per share in Indonesia was effective on 27 September 1995. In relation to the offering the new shares, the Government of the Republic of Indonesia also offered 125,825,000 B class shares which were represented by 12,582,500 GDR (each GDR representing 10 B class shares) to the public outside Indonesia. Gross profit for 1999 stand at Rp 751 billion, a figure 45% lower than that achieved in 1998, when gross profits reached Rp 1,362 billion.
Selengkapnya di halaman TINS →PT. Tempo Scan Pacific Tbk (the Company) was established in the Republic of Indonesia dated 20 May 1970, under its original name PT Scanchemie within the framework of the Domestic Capital Investment Law No. 6 year 1968, as amended by Law No. 12 year 1970, based on Notarial Deed No. 37 of Ridwan Suselo, S.H. The company is famous for such pharmaceutical products as Bodrex, Hemaviton and Neo-Rheumacyl.
Selengkapnya di halaman TSPC →